Middle East and Africa biosimilars market seen reaching $5.73 billion by 2035

The Middle East and Africa biosimilars market is estimated to grow from USD 1.15 billion in the current year to USD 5.73 billion by 2035 at a CAGR of 19% during the forecast period, till 2035. The biosimilars market in the Middle East and Africa is currently experiencing rapid growth, fueled by increased healthcare investments, a rising prevalence of chronic diseases such as diabetes and cancer, and favorable regulatory environments in prominent countries like Saudi Arabia, the UAE, and South Africa.

The biosimilars market is expected to grow significantly in the upcoming years as patents of biologics expire, paving the way for the introduction of biosimilars that closely mimic their original counterparts. Lately, the biologics sector has experienced considerable expansion, largely due to its increased effectiveness in managing chronic diseases.

The Middle East and Africa biosimilars market experiences robust growth driven by several key factors, including rising prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders and increased demand for affordable biologic alternatives. Government initiatives such as streamlined regulatory pathways for biologics also propel market growth, while patent expiries of major drugs like Herceptin and Rituxan enable local manufacturers to expand portfolios rapidly.

Challenges persist despite the ongoing market growth, hindering faster adoption. High development costs, complex manufacturing processes requiring stringent quality controls, and risks of immunogenicity or structural variability raise entry barriers for smaller players, while evolving guidelines and the need for comparative clinical trials result in delayed approvals.

Poor domestic production and R&D infrastructure in the region lead to import dependency and supply disruptions. Market access issues, such as competition from branded generics, pricing pressures, and patent litigations from originator companies, also constrain growth.

At present, the monoclonal antibodies segment holds almost 55% of the total market share in Middle East and Africa, mainly due to their widespread application in the treatment of chronic illnesses such as cancer, rheumatoid arthritis, and various autoimmune disorders. However, the peptide segment is expected to expand at a faster CAGR throughout the forecast period.

Currently, oncological disorders dominate the Middle East and Africa biosimilars market, supported by an aging population, changes in lifestyle, and improved diagnostic techniques, necessitating affordable treatments, particularly for costly monoclonal antibody therapies. The hematological disorders segment is expected to experience a higher compound annual growth rate during the forecast period.